The Effect of Standard vs. Shorter Filter Lifespan During Continuous Renal Replacement Therapy

NCT07630220 | Not Yet Recruiting

• 2 other identifiers: AnIt26-02DRKS00039623
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate shorter vs. standard filter lifespans in critically ill patients receiving continuous renal replacement therapy (CRRT) for acute kidney injury (AKI). The aim of this trial is to reliably implement,scheduled filter changes and to investigate whether shorter filter lifetime is associated with a lower incidence in rate of new infections.

Conditions

Acute Kidney Injury

Keywords

Continuous Renal Replacement Therapy (CRRT); Infection; filter change; critical illness

Outcome Measures

Primary Outcomes (2)

• Mean filter lifespan per patient

  Comparison of mean filter lifespans between study groups

  From start of CRRT to end of CRRT or at day 30 after randomization, whatever occurs first

• Protocol adherence as documented filter change within the specified period

  Proportion of protocol adherent patients, defined as patients with mean filter lifespan within the pre-specified time window in each arm (intervention group: 36±3hours; control group: 48-72hours

  From start of CRRT to end of CRRT or at day 30 after randomization, whatever occurs first

Secondary Outcomes (1)

• New intensive care unit-associated acquired infection up to day 30

  From start of CRRT to end of CRRT or at day 30 after randomization, whatever occurs first

Study Arms (2)

Early filter change

EXPERIMENTAL

Scheduled filter change during continuous renal replacement therapy at 36 ± 3 hours.

Other: time span of filter change

Standard of Care filter change

ACTIVE COMPARATOR

Standard of care with scheduled filter change during continuous renal replacement therapy at 72 hours.

Other: time span of filter change

Interventions

time span of filter change OTHER

The time span of the filter change during continuous renal replacement therapy will be specified

Early filter change; Standard of Care filter change

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult ≥ 18 years
• Critically ill patients with severe AKI consistent with KDIGO stage 3 and an absolute indication for CRRT

You may not qualify if:

• End-stage kidney disease or chronic dialysis dependence
• Chronic kidney disease with eGFR\<20ml/min/1.73 m²
• Prior kidney transplant
• Prior renal replacement therapy during the index admission before randomization
• Glomerulonephritis, interstitial nephritis, vasculitis
• Patients on immunosuppression (above the cushing threshold)
• Patients with chronic inflammatory diseases (e.g. arthritis, HIV with a CD4 count of \< 0.05 x 10E/l)
• Do-not resuscitate order
• Persons with any kind of dependency on the investigator or employed by the sponsor
• Patients participating in an interventional study involving measures to influence the immune system

Sponsors & Collaborators

• Universität Münster: lead

Study Sites (1)

University Hospital Münster

Münster, 48149, Germany

Location

Related Publications (2)

• Gerss J, Meersch M, Kindgen-Milles D, Brandenburger T, Willam C, Kellum JA, Zarbock A. The Effect of Filter Lifespan during Continuous Renal Replacement Therapy in Critically Ill Patients with Acute Kidney Injury on the Rate of New-Onset Infection: Analysis from the RICH Randomized Controlled Trial. Am J Respir Crit Care Med. 2022 Aug 15;206(4):511-514. doi: 10.1164/rccm.202201-0063LE. No abstract available.

  PMID: 35549654 BACKGROUND

• Zarbock A, Kullmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, Dimski T, Tyczynski B, Jahn M, Mulling N, Mehrlander M, Rosenberger P, Marx G, Simon TP, Jaschinski U, Deetjen P, Putensen C, Schewe JC, Kluge S, Jarczak D, Slowinski T, Bodenstein M, Meybohm P, Wirtz S, Moerer O, Kortgen A, Simon P, Bagshaw SM, Kellum JA, Meersch M; RICH Investigators and the Sepnet Trial Group. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020 Oct 27;324(16):1629-1639. doi: 10.1001/jama.2020.18618.

  PMID: 33095849 BACKGROUND

MeSH Terms

Conditions

Acute Kidney Injury; Infections; Critical Illness

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Alexander Zarbock, MD

  University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy

  STUDY CHAIR

Central Study Contacts

Alexander Zarbock, MD

CONTACT

+49-251-8347255; zarbock@uni-muenster.de

Nadja Schöne, MD

CONTACT

+49-8347262; nadja.schoene@ukmuenster.de

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 1, 2026
• First Posted: June 5, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2028
• Last Updated: June 5, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

DE (1)